Overview We are a biopharmaceutical royalty company focused on deploying capital and licensing technologies to acquire and create diversified royalty streams from high-value medicines. Our primary business is investing in and structuring royalty interests in mid- to late-stage development and commercial biopharmaceutical products, allowing us to generate long-duration, non-dilutive cash flows supported by a lean corporate cost structure. Capital deployment and technology licensing are the primar...
Q2 FY2026 — expected 2026-09-08
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-27 | 2025-12-31 | 0000886163-26-000006 | EDGAR | 88K words |
| 2025-02-28 | 2024-12-31 | 0000886163-25-000012 | EDGAR | — |
| 2024-02-29 | 2023-12-31 | 0000886163-24-000009 | EDGAR | — |
| 2023-02-28 | 2022-12-31 | 0000886163-23-000007 | EDGAR | — |
| 2022-02-28 | 2021-12-31 | 0000886163-22-000030 | EDGAR | — |
| 2021-02-24 | 2020-12-31 | 0000886163-21-000050 | EDGAR | — |
| 2020-02-27 | 2019-12-31 | 0000886163-20-000025 | EDGAR | — |
| 2019-02-28 | 2018-12-31 | 0000886163-19-000041 | EDGAR | — |
| 2018-03-01 | 2017-12-31 | 0000886163-18-000030 | EDGAR | — |
| 2017-02-28 | 2016-12-31 | 0000886163-17-000021 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-07 | 2025-09-30 | 0000886163-25-000063 | EDGAR | 31K words |
| 2025-08-08 | 2025-06-30 | 0000886163-25-000051 | EDGAR | — |
| 2025-05-09 | 2025-03-31 | 0000886163-25-000036 | EDGAR | — |
| 2024-11-08 | 2024-09-30 | 0000886163-24-000078 | EDGAR | — |
| 2024-08-07 | 2024-06-30 | 0000886163-24-000071 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0000886163-24-000032 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000886163-23-000086 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0000886163-23-000050 | EDGAR | — |
| 2023-05-08 | 2023-03-31 | 0000886163-23-000027 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0000886163-22-000135 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0000886163-22-000117 | EDGAR | — |
| 2022-05-09 | 2022-03-31 | 0000886163-22-000049 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-26 | 0000886163-26-000003 | EDGAR | 7K words |
| 2025-12-18 | 0001193125-25-324830 | EDGAR | — |
| 2025-11-06 | 0000886163-25-000058 | EDGAR | — |
| 2025-09-16 | 0001193125-25-205147 | EDGAR | — |
| 2025-08-14 | 0001193125-25-180841 | EDGAR | — |
| 2025-08-11 | 0001193125-25-177452 | EDGAR | — |
| 2025-08-07 | 0000886163-25-000047 | EDGAR | — |
| 2025-07-02 | 0000886163-25-000042 | EDGAR | — |
| 2025-06-09 | 0000886163-25-000040 | EDGAR | — |
| 2025-05-08 | 0000886163-25-000033 | EDGAR | — |
257 total filings indexed. 225 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000886163 |
| Ticker | LGND |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.ligand.com |
| Listed | 1994-11-25 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report